Related Experiment Video

Updated: Jun 17, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

CDK9 inhibitors for the treatment of solid tumors

Christiana Mo1, Ning Wei2, Terence Li2

  • 1Department of Oncology, Montefiore Einstein, Bronx, NY, USA; Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA.

Biochemical Pharmacology
|August 10, 2024
PubMed

Insights

Cyclin-dependent kinase 9 (CDK9) is a key regulator of transcription overexpressed in many cancers. This review explores CDK9

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Cyclin-dependent kinase 9 (CDK9) plays a crucial role in regulating mRNA transcription through RNA Polymerase II (Pol II) elongation.
  • Overexpression of CDK9 is linked to cancer development and poorer clinical outcomes, establishing it as a significant cancer driver.
  • While CDK9 inhibition has been extensively studied in hematologic cancers, its role in solid tumors is gaining attention.

Purpose of the Study:

  • To review the current understanding of CDK9 biology in the context of solid tumors.
  • To summarize the development and studies of small molecule CDK9 inhibitors.
  • To discuss recent clinical trial outcomes and strategies for enhancing the therapeutic efficacy of CDK9 inhibitors in solid tumors.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of CDK9's role in oncogenic signaling pathways in solid tumors.
  • Evaluation of small molecule CDK9 inhibitors and their clinical performance.

Main Results:

  • CDK9 overexpression is prevalent in various solid tumors, driving oncogenic pathways.
  • Small molecule CDK9 inhibitors show promise but face challenges in clinical application.
  • Recent clinical trials provide insights into the efficacy and limitations of CDK9 inhibitors.

Conclusions:

  • CDK9 is a viable therapeutic target for solid tumors, with ongoing research into optimizing inhibitor strategies.
  • Further investigation is needed to overcome resistance mechanisms and improve patient outcomes with CDK9 inhibitors.
  • Enhancing the therapeutic impact of CDK9 inhibitors requires a focused approach on specific solid tumor contexts and combination therapies.
Keywords:
CDK9Cancer therapeuticsSolid tumorsTargeted therapy

More Related Videos

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.6K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K